At a glance

ClinicalIndex Comparison Record

N/ARecruiting· 174 target

Drug / intervention

Esketamine group +1 moredrug

Likely dose

Esketamine group 0.5mg/kgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06890897

NCT06890897N/ARecruitingOn TrackUpdated 14mo ago

Compare CT.gov

Effect of Intravenous Infusion of Esketamine Combined Pulsed Radiofrequency on Acute/Subacute Zoster-associated Trigeminal Neuralgia

Beijing Tiantan Hospital·interventional·Posted Mar 24, 2025·Updated Apr 27, 2025

In Brief

A clinical study evaluating Esketamine group and PRF group for Zoster; Herpes, Trigeminal Neuralgia (Etiology). Currently recruiting, targeting 174 participants across 1 site.

Detailed Summary

To assess the 1-month effects and safety of esketamine combined PRF and standardized treatment to relieve pain in patients with acute/subacute zoster-related trigeminal neuralgia(ZRTN).

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsZoster; Herpes, Trigeminal Neuralgia (Etiology)

CountriesChina

CollaboratorsBeijing Xiaotangshan Hospital, The First Hospital of Fangshan District,Beijing, Beijing Ditan Hospital, Hengshui People's Hospital

Timeline

N/ARecruiting

2026

First PostedMar 2025

Enrollment StartApr 2025

Primary CompletionJun 2026

TodayJul 2026

Study CompletionSep 2026

First PostedMar 24, 2025

Enrollment StartApr 1, 2025

Primary CompletionJun 30, 2026

Study CompletionSep 30, 2026

TodayJul 1, 2026

Enrollment to primary: 1.2 yearsPosted 1.3 years ago

Interventions

Esketamine groupdrug

Patients in the esketamine group will receive intravenous infusion of esketamine besides PRF+standardized treatment.The formula will be intravenous infusion of 0.5mg/kg of esketamine diluted in 50 mL normal saline, starting with intravenous injection of 10 mg of esketamine for 1 minute, and maintaining a dose 8 mg/h.The infusion rate will be adjusted the parameter according to the tolerance of the patients

PRF groupdrug

Patients in the control group will receive PRF+standardized treatment